NDATOPICALCREAM
Approved
Dec 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
SOOLANTRA (ivermectin) by Galderma is 12. Approved for rosacea. First approved in 2014.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SOOLANTRA (ivermectin 1% cream) is a topical antiparasitic agent approved for rosacea treatment, though its exact mechanism in this indication remains unknown. It is systemically absorbed with minimal plasma accumulation over extended treatment periods and is primarily metabolized via CYP3A4 without significant drug-drug interactions.
$2MPart D
Peak7.9 years to LOESOOLANTRA is in peak lifecycle with stable modest spending ($2M Part D, 2,721 claims in 2023); the brand team is likely lean and focused on maintenance rather than expansion.
Mechanism of Action
12.1 Mechanism of Action The mechanism of action of ivermectin cream in treating rosacea lesions is unknown. 12.2 Pharmacodynamics Cardiac Electrophysiology At therapeutic doses, ivermectin cream is not expected to prolong QTc interval. 12.3 Pharmacokinetics Absorption The absorption of ivermectin…
Pharmacologic Class:
Antiparasitic
Indications (1)
Worked on SOOLANTRA at Galderma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.